Enzastaurin in Treating Young Patients With Refractory Primary CNS Tumors
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Enzastaurin may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth and by blocking blood flow to the tumor.
PURPOSE: This phase I trial is studying the side effects and best dose of enzastaurin in
treating young patients with refractory primary brain tumors.